Floatz logo

Zoledronate

Clear Cell Renal Carcinoma

Kelly Fitzgerald, MDSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Clear Cell Renal Carcinoma cohort.

Asset / SponsorPhaseRating
Everolimus
Peking University First Hospital
Phase 2BB
Axitinib
University of California, San Francisco
Phase 3B
MODIFIED VACCINIA VIRUS ANKARA-5T4 ANTIGEN
Oxford BioMedica
Phase 3B
Toripalimab
RenJi Hospital
Phase 2B
Ivonescimab
City of Hope Medical Center
Phase 2CCC

View all 15 →

Same molecule, other indications

Zoledronate is also rated in:

metastatic carcinoma in the boneDormant
BBB
Indicative ·
79 / 100
View asset →
osteoporosisDormant
BBB
Indicative ·
76 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →